Results 161 to 170 of about 149,070 (296)

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a 3 comprehensive overview of targeted approaches. [PDF]

Front Oncol
Deshpande S, Li WF, Song J, Forsberg M, Cerchione C, Martinelli G, Konopleva M.   +6 more
europepmc   +1 more source

TP53 mutations and loss of heterozygosity of chromosome 17 in colorectal tumors [PDF]

, 1996
Lídia Yamamoto, Ademar A. Lopes, Angelito Harb-Gama, María Aparecida Nagai   +3 more
openalex   +1 more source

Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy

, 2022
Abhay Singh, Nuria Mencia-Trinchant, Elizabeth A. Griffiths, Alaa Altahan, Mahesh Swaminathan, Medhavi Gupta, Matthew Gravina, Rutaba Tajammal, Mark G. Faber, LunBiao Yan, Eti Sinha, Duane C. Hassane, David Neil Hayes, Monica L. Guzman, Renuka Iyer, Eunice S. Wang, Swapna Thota   +16 more
openalex   +2 more sources

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

International Journal of Cancer, EarlyView.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang, Shuai Zhou, Xiongchao Fang, Xianli He, Gang Wang, Nan Wang   +5 more
wiley   +1 more source

Tumor Suppressor p53 and MicroRNAs Interaction in Breast Cancer. [PDF]

Oncol Res
Luna MEV, Lourenço GJ, Carron J.
europepmc   +1 more source

TP53 (gene)

, 2017
Frank Gaillard, Yuranga Weerakkody, Daniel Bell   +2 more
openaire   +1 more source

PVT1 lincRNA signals an androgen‐dependent transcriptional activation program of oncogenes in prostate cancer cells

International Journal of Cancer, EarlyView.
What's New? Unraveling the networks that regulate androgen receptor (AR) function is critical to better understanding prostate cancer development and progression. Of particular interest in this regard is the long non‐coding RNA PVT1, which regulates gene expression in cancer and is upregulated in prostate tumors.
Maria Gabriela Berzoti‐Coelho, Fabio Nunes de Mello, Ana Carolina Tahira, Gabriel Nakanishi Fortes, Agatha Fischer‐Carvalho, Pedro Jardim Poli, Murilo Sena Amaral, Sergio Verjovski‐Almeida   +7 more
wiley   +1 more source

Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma. [PDF]

Ann Hematol
Yu J, He Q, Yan Y, Liu K, Xie R, Ma J, Wang L.   +6 more
europepmc   +1 more source

Systematic Inspection of the Clinical Relevance of TP53 Missense Mutations in Gastric Cancer [PDF]

, 2018
Seong Ryeol Moon, Curt Balch, Sungjin Park, Jinhyuk Lee, Ji‐Yong Sung, Seungyoon Nam   +5 more
openalex   +1 more source